Targeting HIF-1 for prostate cancer: a synthesis of preclinical evidence

References

• Wang GL, Jiang BH, Rue EA, et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci, USA. 1995;92:5510–5514. Available from https://pnas.org/doi/full/10.1073/pnas.92.12.5510.
   PubMed Web of Science ®Google Scholar
• Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem. 1995;270(3):1230–1237. doi: 10.1074/jbc.270.3.1230
   PubMed Web of Science ®Google Scholar
• Jiang B-H, Rue E, Wang GL, et al. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem. 1996;271(30):17771–17778. doi: 10.1074/jbc.271.30.17771
   PubMed Web of Science ®Google Scholar
• YANG C, ZHONG Z-F, WANG S-P, et al. HIF-1: structure, biology and natural modulators. Chin J Nat Med. 2021;19:521–527. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1875536421600511
   PubMed Web of Science ®Google Scholar
• Malkov MI, Lee CT, Taylor CT. Regulation of the hypoxia-inducible factor (HIF) by pro-inflammatory cytokines. Cells. 2021;10(9):2340. doi: 10.3390/cells10092340
   PubMed Web of Science ®Google Scholar
• Ratcliffe PJ. HIF-1 and HIF-2: working alone or together in hypoxia? J Clin Investig. 2007;117(4):862–865. doi: 10.1172/JCI31750
   PubMed Web of Science ®Google Scholar
• Hirota K, Semenza GL. Regulation of angiogenesis by hypoxia-inducible factor 1. Crit Rev Oncol Hematol. 2006;59(1):15–26. doi: 10.1016/j.critrevonc.2005.12.003
   PubMed Web of Science ®Google Scholar
• Taylor SE, Bagnall J, Mason D, et al. Differential sub-nuclear distribution of hypoxia-inducible factors (HIF)-1 and -2 alpha impacts on their stability and mobility. Open Biol. 2016;6(9):160195. doi: 10.1098/rsob.160195
   PubMed Web of Science ®Google Scholar
• Shi Y-H, Fang W-G. Hypoxia-inducible factor-1 in tumour angiogenesis. World J Gastroenterol. 2004;10(8):1082. doi: 10.3748/wjg.v10.i8.1082
   PubMed Web of Science ®Google Scholar
• Jin X, Dai L, Ma Y, et al. Implications of HIF-1α in the tumorigenesis and progression of pancreatic cancer. Cancer Cell Int. 2020;20(1):273. doi: 10.1186/s12935-020-01370-0
   PubMed Web of Science ®Google Scholar
• Masoud GN, Li W. HIF-1α pathway: role, regulation and intervention for cancer therapy. Acta Pharm Sin B. 2015;5(5):378–389. doi: 10.1016/j.apsb.2015.05.007
   PubMed Web of Science ®Google Scholar
• Iommarini L, Porcelli AM, Gasparre G, et al. Non-Canonical mechanisms regulating hypoxia-inducible factor 1 alpha in cancer. Front Oncol. 2017;7. doi: 10.3389/fonc.2017.00286.
   PubMed Web of Science ®Google Scholar
• Miao M, Wu M, Li Y, et al. Clinical potential of hypoxia inducible factors prolyl hydroxylase inhibitors in treating nonanemic diseases. Front Pharmacol [Internet]. 2022;13.
   Web of Science ®Google Scholar
• Wei J, Yang Y, Lu M, et al. Recent advances in the discovery of HIF-1α-p300/CBP inhibitors as anti-cancer agents. Mini-Rev Med Chem [Internet]. 2018;18. doi: 10.2174/1389557516666160630124938
   PubMed Web of Science ®Google Scholar
• Yang C, Wang W, Li G-D, et al. Anticancer osmium complex inhibitors of the HIF-1α and p300 protein-protein interaction. Sci Rep [Internet]. 2017;7(1):42860. doi: 10.1038/srep42860
   PubMedGoogle Scholar
• Cohen M, Amir S, Golan M, et al. β-TrCP upregulates HIF-1 in prostate cancer cells. Prostate [Internet]. 2019;79(4):403–413. doi: 10.1002/pros.23746
   PubMed Web of Science ®Google Scholar
• Amir S, Golan M, Mabjeesh NJ. Targeted knockdown of SEPT9_v1 inhibits tumor growth and angiogenesis of human prostate cancer cells concomitant with disruption of hypoxia-inducible factor-1 pathway. Mol Cancer Res. 2010 [Internet];8(5):643–652. doi: 10.1158/1541-7786.MCR-09-0497
   PubMed Web of Science ®Google Scholar
• Golan M, Mabjeesh NJ. Imaging of hypoxia-inducible factor 1α and septin 9 interaction by bimolecular fluorescence complementation in live cancer cells. Oncotarget. 2017 [Internet];8(19):31830–31841. doi: 10.18632/oncotarget.16527
   PubMedGoogle Scholar
• Paatero I, Jokilammi A, Heikkinen PT, et al. Interaction with ErbB4 promotes hypoxia-inducible factor-1α signaling. J Biol Chem [Internet]. 2012;287(13):9659–9671. doi: 10.1074/jbc.M111.299537
   PubMed Web of Science ®Google Scholar
• Takeda N, O’Dea EL, Doedens A, et al. Differential activation and antagonistic function of HIF-α isoforms in macrophages are essential for NO homeostasis. Genes Dev [Internet]. 2010;24(5):491–501. doi: 10.1101/gad.1881410
   PubMed Web of Science ®Google Scholar
• Kristan A, Debeljak N, Kunej T. Integration and visualization of regulatory elements and variations of the EPAS1 gene in human. Genes (Basel). 2021 [Internet];12(11):1793. doi: 10.3390/genes12111793
   PubMed Web of Science ®Google Scholar
• Zhdanov AV, Dmitriev RI, Golubeva AV, et al. Chronic hypoxia leads to a glycolytic phenotype and suppressed HIF-2 signaling in PC12 cells. Biochim Biophys Acta Gen Subj. 2013;1830:3553–3569. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0304416513000597
   PubMed Web of Science ®Google Scholar
• Toschi A, Lee E, Thompson S, et al. Phospholipase D-mTOR requirement for the Warburg effect in human cancer cells. Cancer Lett [Internet]. 2010;299(1):72–79. doi: 10.1016/j.canlet.2010.08.006
   PubMed Web of Science ®Google Scholar
• Compernolle V, Brusselmans K, Acker T, et al. Loss of HIF-2α and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med [Internet]. 2002;8(7):702–710. doi: 10.1038/nm721
   PubMed Web of Science ®Google Scholar
• Mohlin S, Hamidian A, von Stedingk K, et al. PI3K–mTORC2 but not PI3K–mTORC1 regulates transcription of HIF2A/EPAS1 and vascularization in neuroblastoma. Cancer Res [Internet]. 2015;75(21):4617–4628. doi: 10.1158/0008-5472.CAN-15-0708
   PubMed Web of Science ®Google Scholar
• Peng X, Gao H, Xu R, et al. Correction to: the interplay between HIF-1α and noncoding RNAs in cancer. J Exp Clin Cancer Res [Internet]. 2020;39(1):45. doi: 10.1186/s13046-020-01544-8
   PubMed Web of Science ®Google Scholar
• Na Y-R, Han K-C, Park H, et al. Menadione and ethacrynic acid inhibit the hypoxia-inducible factor (HIF) pathway by disrupting HIF-1α interaction with p300. Biochem Biophys Res Commun [Internet]. 2013;434(4):879–884. doi: 10.1016/j.bbrc.2013.04.044
   PubMed Web of Science ®Google Scholar
• Lv X, Li J, Zhang C, et al. The role of hypoxia-inducible factors in tumor angiogenesis and cell metabolism. Genes Dis [Internet]. 2017;4(1):19–24. doi: 10.1016/j.gendis.2016.11.003
   PubMed Web of Science ®Google Scholar
• Kierans SJ, Taylor CT. Regulation of glycolysis by the hypoxia‐inducible factor (HIF): implications for cellular physiology. J Physiol. 2021 [Internet];599(1):23–37. doi: 10.1113/JP280572
   PubMed Web of Science ®Google Scholar
• Ioannidou E, Moschetta M, Shah S, et al. Angiogenesis and anti-angiogenic treatment in prostate cancer: mechanisms of action and molecular targets. Int J Mol Sci [Internet]. 2021;22(18):9926. doi: 10.3390/ijms22189926
   PubMed Web of Science ®Google Scholar
• Haase VH. Hypoxia-inducible factors in the kidney. Am J Physiol Renal Physiol. 2006 [Internet];291(2):F271–F281. doi: 10.1152/ajprenal.00071.2006
   PubMed Web of Science ®Google Scholar
• Jelkmann W. Erythropoietin after a century of research: younger than ever. Eur J Haematol. 2007 [Internet];78(3):183–205. doi: 10.1111/j.1600-0609.2007.00818.x
   PubMed Web of Science ®Google Scholar
• Abdu A, Arogundade F, Adamu B, et al. Anaemia and its response to treatment with recombinant human erythropoietin in chronic kidney disease patients. West Afr J Med. 2010;28. Available from: http://www.ajol.info/index.php/wajm/article/view/55003
   Google Scholar
• Semba H, Takeda N, Isagawa T, et al. HIF-1α-PDK1 axis-induced active glycolysis plays an essential role in macrophage migratory capacity. Nat Commun [Internet]. 2016;7(1):11635. doi: 10.1038/ncomms11635
   PubMed Web of Science ®Google Scholar
• Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell. 2012 [Internet];148(3):399–408. doi: 10.1016/j.cell.2012.01.021
   PubMed Web of Science ®Google Scholar
• Moslehi J, Rathmell WK. The 2019 nobel prize honors fundamental discoveries in hypoxia response. Journal Of Clinical Investigation. 2019;130(1):4–6. Available from: https://www.jci.org/articles/view/134813
   Web of Science ®Google Scholar
• Hirota K. Hypoxia-dependent signaling in perioperative and critical care medicine. J Anesth. 2021;35(5):741–756. doi: 10.1007/s00540-021-02940-w
   PubMed Web of Science ®Google Scholar
• Loenarz C. An oxygen sensation: progress in macromolecule hydroxylation triggered by the elucidation of cellular oxygen sensing. Angew Chem Int Ed. 2020;59:3776–3780. Available from: https://onlinelibrary.wiley.com/doi/10.1002/anie.201913263
   PubMed Web of Science ®Google Scholar
• Végran F, Boidot R, Michiels C, et al. Lactate Influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-κB/IL-8 pathway that drives tumor angiogenesis. Cancer Res [Internet]. 2011;71(7):2550–2560. doi: 10.1158/0008-5472.CAN-10-2828
   PubMed Web of Science ®Google Scholar
• Mullen AR, Wheaton WW, Jin ES, et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature [Internet]. 2012;481(7381):385–388. doi: 10.1038/nature10642
   Web of Science ®Google Scholar
• Hu H, Takano N, Xiang L, et al. Hypoxia-inducible factors enhance glutamate signaling in cancer cells. Oncotarget [Internet]. 2014;5(19):8853–8868. doi: 10.18632/oncotarget.2593
   PubMedGoogle Scholar
• Jun JC, Rathore A, Younas H, et al. Hypoxia-inducible factors and cancer. Curr Sleep Med Rep. 2017;3:1–10. Available from: http://link.springer.com/10.1007/s40675-017-0062-7
   PubMedGoogle Scholar
• Colgan SP, Furuta GT, Taylor CT. Hypoxia and Innate immunity: keeping up with the HIFsters. Annu Rev Immunol. 2020 [Internet];38(1):341–363. doi: 10.1146/annurev-immunol-100819-121537
   PubMedGoogle Scholar
• McGettrick AF, O’Neill LAJ. The role of HIF in immunity and inflammation. Cell Metab [Internet]. 2020;32(4):524–536. doi: 10.1016/j.cmet.2020.08.002
   PubMed Web of Science ®Google Scholar
• Hsu T-S, Lin Y-L, Wang Y-A, et al. HIF-2α is indispensable for regulatory T cell function. Nat Commun [Internet]. 2020;11(1):5005. doi: 10.1038/s41467-020-18731-y
   PubMed Web of Science ®Google Scholar
• Shi LZ, Wang R, Huang G, et al. HIF1α–dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and treg cells. J Exp Med [Internet]. 2011;208(7):1367–1376. doi: 10.1084/jem.20110278
   PubMed Web of Science ®Google Scholar
• Budda SA, Girton A, Henderson JG, et al. Transcription factor HIF-1α controls expression of the cytokine IL-22 in CD4 T cells. J Immunol [Internet]. 2016;197(7):2646–2652. doi: 10.4049/jimmunol.1600250
   PubMed Web of Science ®Google Scholar
• Taylor CT, Colgan SP. Regulation of immunity and inflammation by hypoxia in immunological niches. Nat Rev Immunol. 2017 [Internet];17(12):774–785. doi: 10.1038/nri.2017.103
   PubMed Web of Science ®Google Scholar
• Mingyuan X, Qianqian P, Shengquan X, et al. Hypoxia-inducible factor-1α activates transforming growth factor-β1/Smad signaling and increases collagen deposition in dermal fibroblasts. Oncotarget. 2018;9(3):3188–3197. doi: 10.18632/oncotarget.23225
   PubMedGoogle Scholar
• Taylor CT, Kent BD, Crinion SJ, et al. Human adipocytes are highly sensitive to intermittent hypoxia induced NF-kappaB activity and subsequent inflammatory gene expression. Biochem Biophys Res Commun [Internet]. 2014;447(4):660–665. doi: 10.1016/j.bbrc.2014.04.062
   PubMed Web of Science ®Google Scholar
• Ando A, Hashimoto N, Sakamoto K, et al. Repressive role of stabilized hypoxia inducible factor 1α expression on transforming growth factor β‐induced extracellular matrix production in lung cancer cells. Cancer Sci [Internet]. 2019;110(6):1959–1973. doi: 10.1111/cas.14027
   PubMed Web of Science ®Google Scholar
• Zhong H, Chiles K, Feldser D, et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res . 2000 [cited 2000 Mar 15];60: 1541–1545. Available from http://www.ncbi.nlm.nih.gov/pubmed/10749120
   PubMed Web of Science ®Google Scholar
• Paul SAM, Simons JW, Mabjeesh NJ. HIF at the crossroads between ischemia and carcinogenesis. J Cell Physiol. 2004 [Internet];200(1):20–30. doi: 10.1002/jcp.10479
   PubMed Web of Science ®Google Scholar
• Hui AS, Bauer AL, Striet JB, et al. Calcium signaling stimulates translation of HIF‐α during hypoxia. FASEB J [Internet]. 2006;20(3):466–475. doi: 10.1096/fj.05-5086com
   PubMed Web of Science ®Google Scholar
• Manisterski M, Golan M, Amir S, et al. Hypoxia induces PTHrP gene transcription in human cancer cells through the HIF-2α. Cell Cycle [Internet]. 2010;9(18):3747–3753. doi: 10.4161/cc.9.18.12931
   Web of Science ®Google Scholar
• Liao J, Li X, Koh AJ, et al. Tumor expressed PTHrP facilitates prostate cancer-induced osteoblastic lesions. Int J Cancer [Internet]. 2008;123(10):2267–2278. doi: 10.1002/ijc.23602
   PubMed Web of Science ®Google Scholar
• Zhang Z, Karthaus WR, Lee YS, et al. Tumor microenvironment-derived NRG1 promotes antiandrogen resistance in prostate cancer. Cancer Cell [Internet]. 2020;38(2):279–296.e9. doi: 10.1016/j.ccell.2020.06.005
   PubMed Web of Science ®Google Scholar
• Hong S-S, Lee H, Kim K-W. HIF-1α: a Valid therapeutic target for tumor therapy. Cancer Res Treat. 2004 [Internet];36(6):343. doi: 10.4143/crt.2004.36.6.343
   PubMedGoogle Scholar
• Kim LC, Simon MC. Hypoxia-inducible factors in cancer. Cancer Res. 2022;82:195–196. Available from: https://aacrjournals.org/cancerres/article/82/2/195/675484/Hypoxia-Inducible-Factors-in-CancerHypoxia
   PubMedGoogle Scholar
• Patel SA, Simon MC. Biology of hypoxia-inducible factor-2α in development and disease. Cell Death Differ. 2008 [Internet];15(4):628–634. doi: 10.1038/cdd.2008.17
   PubMed Web of Science ®Google Scholar
• Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Sci (1979). 2009 [Internet];324(5930):1029–1033. doi: 10.1126/science.1160809
   PubMed Web of Science ®Google Scholar
• Li Y, Sun X-X, Qian DZ, et al. Molecular crosstalk between MYC and HIF in cancer. Front Cell Dev Biol [Internet]. 2020;8.
   Web of Science ®Google Scholar
• Aponte PM, Caicedo A. Stemness in cancer: Stem cells, cancer stem cells, and their microenvironment. Stem Cells Int [Internet]. 2017;2017:1–17. doi: 10.1155/2017/5619472
   Web of Science ®Google Scholar
• Yun Z, Lin Q. Hypoxia and regulation of cancer cell stemness. Adv Exp Med Biol. 2014;41–53. Available from: https://link.springer.com/10.1007/978-1-4614-5915-6_2
   PubMed Web of Science ®Google Scholar
• Shah S, Rachmat R, Enyioma S, et al. BRCA mutations in prostate cancer: assessment, implications and treatment considerations. Int J Mol Sci [Internet]. 2021;22(23):12628. doi: 10.3390/ijms222312628
   PubMed Web of Science ®Google Scholar
• Ni Raghallaigh H, Eeles R. Genetic predisposition to prostate cancer: an update. Fam Cancer. 2022 [Internet];21(1):101–114. doi: 10.1007/s10689-021-00227-3
   PubMed Web of Science ®Google Scholar
• Attard G, Murphy L, Clarke NW, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet [Internet]. 2022;399(10323):447–460. doi: 10.1016/S0140-6736(21)02437-5
   PubMed Web of Science ®Google Scholar
• Milosevic M, Warde P, Ménard C, et al. Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer. Clin Cancer Res [Internet]. 2012;18(7):2108–2114. doi: 10.1158/1078-0432.CCR-11-2711
   PubMed Web of Science ®Google Scholar
• Tran MGB, Bibby BAS, Yang L, et al. Independence of HIF1a and androgen signaling pathways in prostate cancer. BMC Cancer [Internet]. 2020;20(1):469. doi: 10.1186/s12885-020-06890-6
   PubMed Web of Science ®Google Scholar
• Ablain J, Liu S, Moriceau G, et al. SPRED1 deletion confers resistance to MAPK inhibition in melanoma. J Exp Med [Internet]. 2021;218(3). doi: 10.1084/jem.20201097
   PubMed Web of Science ®Google Scholar
• Kawazoe T, Taniguchi K. The sprouty/spred family as tumor suppressors: coming of age. Cancer Sci. 2019 [Internet];110(5):1525–1535. doi: 10.1111/cas.13999
   PubMed Web of Science ®Google Scholar
• Kachroo N, Valencia T, Warren AY, et al. Evidence for downregulation of the negative regulator SPRED2 in clinical prostate cancer. Br J Cancer [Internet]. 2013;108(3):597–601. doi: 10.1038/bjc.2012.507
   PubMed Web of Science ®Google Scholar
• Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell [Internet]. 2010;18(1):11–22. doi: 10.1016/j.ccr.2010.05.026
   PubMed Web of Science ®Google Scholar
• Jiang C-F, Shi Z-M, Li D-M, et al. Estrogen-induced miR-196a elevation promotes tumor growth and metastasis via targeting SPRED1 in breast cancer. Mol Cancer [Internet]. 2018;17(1):83. doi: 10.1186/s12943-018-0830-0
   PubMedGoogle Scholar
• Seligson DB, Yu H, Tze S, et al. IGFBP-3 nuclear localization predicts human prostate cancer recurrence. Horm Cancer [Internet]. 2013;4(1):12–23. doi: 10.1007/s12672-012-0124-8
   PubMed Web of Science ®Google Scholar
• Mehta HH, Gao Q, Galet C, et al. IGFBP-3 is a metastasis suppression gene in prostate cancer. Cancer Res [Internet]. 2011;71(15):5154–5163. doi: 10.1158/0008-5472.CAN-10-4513
   PubMed Web of Science ®Google Scholar
• Miyata Y, Sakai H, Kanda S, et al. Expression of insulin-like growth factor binding protein-3 before and after neoadjuvant hormonal therapy in human prostate cancer tissues: correlation with histopathologic effects and biochemical recurrence. Urology [Internet]. 2004;63(6):1184–1190. doi: 10.1016/j.urology.2004.02.015
   PubMed Web of Science ®Google Scholar
• Igarashi K, Yui Y, Watanabe K, et al. Molecular evidence of IGFBP-3 dependent and independent VD3 action and its nonlinear response on IGFBP-3 induction in prostate cancer cells. BMC Cancer [Internet]. 2020;20(1):802. doi: 10.1186/s12885-020-07310-5
   PubMed Web of Science ®Google Scholar
• Ranasinghe WKB, Xiao L, Kovac S, et al. The role of hypoxia-inducible factor 1α in determining the properties of castrate-resistant prostate cancers. Agoulnik IU, editor. PLoS One. 2013;8:e54251. Available from: https://dx.plos.org/10.1371/journal.pone.0054251
   PubMed Web of Science ®Google Scholar
• Mei L, Nave K-A. Neuregulin-ERBB signaling in the nervous system and neuropsychiatric diseases. Neuron. 2014 [Internet];83(1):27–49. doi: 10.1016/j.neuron.2014.06.007
   PubMed Web of Science ®Google Scholar
• Xu Y, Li X, Liu X, et al. Neuregulin-1/ErbB signaling and chronic heart failure. Adv Pharmacol. 2010;31–51. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1054358910590021
   PubMedGoogle Scholar
• Mitani T, Harada N, Nakano Y, et al. Coordinated action of hypoxia-inducible factor-1α and β-catenin in androgen receptor signaling. J Biol Chem [Internet]. 2012;287(40):33594–33606. doi: 10.1074/jbc.M112.388298
   PubMed Web of Science ®Google Scholar
• Yang M-H, Wu M-Z, Chiou S-H, et al. Direct regulation of TWIST by HIF-1α promotes metastasis. Nat Cell Biol [Internet]. 2008;10(3):295–305. doi: 10.1038/ncb1691
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhang S, Gao S, et al. HIF-1α, TWIST-1 and ITGB-1, associated with tumor stiffness, as novel predictive markers for the pathological response to neoadjuvant chemotherapy in breast cancer. Cancer Manag Res. 2020;12:2209–2222. Available from: https://www.dovepress.com/hif-1alpha-twist-1-and-itgb-1-associated-with-tumor-stiffness-as-novel-peer-reviewed-article-CMAR
   PubMed Web of Science ®Google Scholar
• Chen P-C, Tai H-C, Lin T-H, et al. CCN3 promotes epithelial-mesenchymal transition in prostate cancer via FAK/Akt/HIF-1α-induced twist expression. Oncotarget [Internet]. 2017;8(43):74506–74518. doi: 10.18632/oncotarget.20171
   PubMedGoogle Scholar
• Børretzen A, Gravdal K, Haukaas SA, et al. The epithelial–mesenchymal transition regulators twist, slug, and snail are associated with aggressive tumour features and poor outcome in prostate cancer patients. J Pathol Clin Res [Internet]. 2021;7(3):253–270. doi: 10.1002/cjp2.202
   PubMedGoogle Scholar
• Abdelrahman AE, Arafa SA, Ahmed RA. Prognostic value of twist-1, e-cadherin and ezh2 in prostate cancer: an immunohistochemical study. Turk J Pathol 2017;33. doi: 10.5146/tjpath.2016.01392
   Google Scholar
• Eisermann K, Fraizer G. The androgen receptor and VEGF: mechanisms of androgen-regulated angiogenesis in prostate cancer. Cancers (Basel). 2017 [Internet];9(12):32. doi: 10.3390/cancers9040032
   PubMedGoogle Scholar
• Mabjeesh NJ, Willard MT, Frederickson CE, et al. Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3’-kinase/protein kinase B in prostate cancer cells. Clin Cancer Res. 2003 [cited 2003 Jul 1];9:2416–2425. Available from http://www.ncbi.nlm.nih.gov/pubmed/12855613
   PubMed Web of Science ®Google Scholar
• Eisermann K, Broderick CJ, Bazarov A, et al. Androgen up-regulates vascular endothelial growth factor expression in prostate cancer cells via an Sp1 binding site. Mol Cancer [Internet]. 2013;12(1):7. doi: 10.1186/1476-4598-12-7
   PubMedGoogle Scholar
• Duque JLF, Loughlin KR, Adam RM, et al. Measurement of plasma levels of vascular endothelial growth factor in prostate cancer patients: relationship with clinical stage, Gleason score, prostate volume, and serum prostate-specific antigen. Clinics [Internet]. 2006 [cited 2006 Jan 23]];61(5):401–408. doi: 10.1590/S1807-59322006000500006
   PubMedGoogle Scholar
• Caine GJ, Ryan P, Lip GYH, et al. Significant decrease in angiopoietin-1 and angiopoietin-2 after radical prostatectomy in prostate cancer patients. Cancer Lett [Internet]. 2007;251(2):296–301. doi: 10.1016/j.canlet.2006.11.026
   PubMed Web of Science ®Google Scholar
• Barata PC, Cooney M, Mendiratta P, et al. Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer. Invest New Drugs [Internet]. 2019;37(2):331–337. doi: 10.1007/s10637-018-0687-5
   PubMed Web of Science ®Google Scholar
• McKay RR, Zurita AJ, Werner L, et al. A randomized phase ii trial of short-course androgen deprivation therapy with or without bevacizumab for patients with recurrent prostate cancer after definitive local therapy. J Clin Oncol [Internet]. 2016;34(16):1913–1920. doi: 10.1200/JCO.2015.65.3154
   PubMed Web of Science ®Google Scholar
• Li H, Wang J, Jin Y, et al. Hypoxia upregulates the expression of lncRNA H19 in non-small cell lung cancer cells and induces drug resistance. Transl Cancer Res TCR [Internet]. 2022;11(8):2876–2886. doi: 10.21037/tcr-22-1812
   PubMed Web of Science ®Google Scholar
• Marengo B, Garbarino O, Speciale A, et al. MYC expression and metabolic redox changes in cancer cells: a synergy able to induce chemoresistance. Oxid Med Cell Longev [Internet]. 2019;2019:1–9. doi: 10.1155/2019/7346492
   Web of Science ®Google Scholar
• Icard P, Shulman S, Farhat D, et al. How the Warburg effect supports aggressiveness and drug resistance of cancer cells? Drug Resist Updat. 2018;38:1–11. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1368764618300219
   PubMed Web of Science ®Google Scholar
• Tan H. The association between hypoxia-inducible factor 1a, autophagy and cell stemness in tumor cells. AIP Conf Proc. 2021;020019. Available from: https://pubs.aip.org/aip/acp/article/731290
   Google Scholar
• Sweeney CJ, Chen Y-H, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med [Internet]. 2015;373(8):737–746. doi: 10.1056/NEJMoa1503747
   PubMed Web of Science ®Google Scholar
• Belkahla S, Nahvi I, Biswas S, et al. Advances and development of prostate cancer, treatment, and strategies: a systemic review. Front Cell Dev Biol [Internet]. 2022;10.
   PubMed Web of Science ®Google Scholar
• Qian DZ, Rey S, Liu JO, et al. Retraction for Lee et al., Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc Natl Acad Sci. 2022;119. Available from: https://pnas.org/doi/full/10.1073/pnas.2213285119
   Web of Science ®Google Scholar
• Laber DA, Eatrides J, Jaglal MV, et al. A phase I/II study of docetaxel in combination with pegylated liposomal doxorubicin in metastatic castration-resistant prostate cancer. Med Oncol. 2020;37:95. Available from: https://link.springer.com/10.1007/s12032-020-01420-7
   PubMed Web of Science ®Google Scholar
• Soung N-K, Kim H-M, Asami Y, et al. Mechanism of the natural product moracin-O derived MO-460 and its targeting protein hnRNPA2B1 on HIF-1α inhibition. Exp Mol Med [Internet]. 2019;51(2):1–14. doi: 10.1038/s12276-018-0200-4
   PubMedGoogle Scholar
• Kang T-S, Wang W, Zhong H-J, et al. An anti-prostate cancer benzofuran-conjugated iridium(III) complex as a dual inhibitor of STAT3 and NF-κB. Cancer Lett [Internet]. 2017;396:76–84. doi: 10.1016/j.canlet.2017.03.016
   PubMed Web of Science ®Google Scholar
• Bertozzi D, Marinello J, Manzo SG, et al. The natural inhibitor of DNA Topoisomerase i, camptothecin, modulates HIF-1α activity by changing miR expression patterns in human cancer cells. Mol Cancer Ther [Internet]. 2014;13(1):239–248. doi: 10.1158/1535-7163.MCT-13-0729
   PubMed Web of Science ®Google Scholar
• Gigliotti CL, Minelli R, Cavalli R, et al. In vitro and in vivo therapeutic evaluation of camptothecin-encapsulated β-cyclodextrin nanosponges in prostate cancer. J Biomed Nanotechnol. 2016;12:114–127. Available from: http://openurl.ingenta.com/content/xref?genre=article&issn=1550-7033&volume=12&issue=1&spage=114
   PubMed Web of Science ®Google Scholar
• Green AK, Corty RW, Wood WA, et al. Comparative effectiveness of mitoxantrone plus prednisone versus prednisone alone in metastatic castrate-resistant prostate cancer after docetaxel failure. Oncology [Internet]. 2015;20(5):516–522. doi: 10.1634/theoncologist.2014-0432
   Google Scholar
• Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol [Internet]. 1999;17(8):2506–2506. doi: 10.1200/JCO.1999.17.8.2506
   PubMed Web of Science ®Google Scholar
• Dueck AC, Scher HI, Bennett AV, et al. Assessment of adverse events from the patient perspective in a phase 3 metastatic castration-resistant prostate cancer Clinical trial. JAMA Oncol. 2020;6:e193332. Available from: https://jamanetwork.com/journals/jamaoncology/fullarticle/2751871
   PubMed Web of Science ®Google Scholar
• Basch EM, Scholz MC, De Bono JS, et al. Final analysis of COMET-2: cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E). J Clin Oncol. 2015;33:141–141. Available from: https://ascopubs.org/doi/10.1200/jco.2015.33.7_suppl.141
   PubMed Web of Science ®Google Scholar
• Karasneh RA, Murray LJ, Hughes CM, et al. Digoxin use after diagnosis of prostate cancer and survival: a population-based cohort study. Pharmacoepidemiol Drug Saf [Internet]. 2016;25(9):1099–1103. doi: 10.1002/pds.4018
   PubMed Web of Science ®Google Scholar
• Lin J, Hoffman-Censits JH, Duffy D, et al. A pilot phase II study of digoxin in patients with recurrent prostate cancer as evident by a rising PSA. J Clin Oncol [Internet]. 2013;31(15_suppl):5061–5061. doi: 10.1200/jco.2013.31.15_suppl.5061
   Google Scholar
• Butt NA, Kumar A, Dhar S, et al. Targeting MTA 1/HIF ‐1 α signaling by pterostilbene in combination with histone deacetylase inhibitor attenuates prostate cancer progression. Cancer Med. 2017;6:2673–2685. Available from: https://onlinelibrary.wiley.com/doi/10.1002/cam4.1209
   PubMed Web of Science ®Google Scholar
• Reece KM, Richardson ED, Cook KM, et al. Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1α/p300 complex in a preclinical model of prostate cancer. Mol Cancer [Internet]. 2014;13(1):91. doi: 10.1186/1476-4598-13-91
   PubMedGoogle Scholar
• Kemp Bohan PM, Chick RC, O’Shea AE, et al. Phase I trial of encapsulated Rapamycin in patients with prostate cancer under active surveillance to prevent progression. Cancer Prev Res [Internet]. 2021;14(5):551–562. doi: 10.1158/1940-6207.CAPR-20-0383
   PubMed Web of Science ®Google Scholar
• Peng J, He Z, Yuan Y, et al. Docetaxel suppressed cell proliferation through Smad3/HIF-1α-mediated glycolysis in prostate cancer cells. Cell Commun Signaling [Internet]. 2022;20(1):194. doi: 10.1186/s12964-022-00950-z
   PubMed Web of Science ®Google Scholar
• Lage DE, Michaelson MD, Lee RJ, et al. Outcomes of older men receiving docetaxel for metastatic hormone-sensitive prostate cancer. Prostate Cancer Prostatic Dis [Internet]. 2021;24(4):1181–1188. doi: 10.1038/s41391-021-00389-2
   PubMed Web of Science ®Google Scholar
• Kyriakopoulos CE, Chen Y-H, Carducci MA, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol [Internet]. 2018;36(11):1080–1087. doi: 10.1200/JCO.2017.75.3657
   PubMed Web of Science ®Google Scholar
• Muldong M, Lee S, Mendoza T, et al. PD07-04 pre-clinical studies for advancing cirmtuzumab-based anti-ror1 therapies in metastatic prostate cancer. J Urol [Internet]. 2022;207(Supplement 5). doi: 10.1097/JU.0000000000002526.04
   Web of Science ®Google Scholar
• ZHENG R-P, WANG W, WEI C-D. Bortezomib inhibits cell proliferation in prostate cancer. Exp Ther Med. 2015 [Internet];10(3):1219–1223. doi: 10.3892/etm.2015.2617
   PubMed Web of Science ®Google Scholar
• Dreicer R, Petrylak D, Agus D, et al. Phase I/II study of Bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. Clin Cancer Res [Internet]. 2007;13(4):1208–1215. doi: 10.1158/1078-0432.CCR-06-2046
   PubMed Web of Science ®Google Scholar
• Kuroda K, Liu H. The proteasome inhibitor, bortezomib, induces prostate cancer cell death by suppressing the expression of prostate-specific membrane antigen, as well as androgen receptor. Int J Oncol. 2019;54. Available from: http://www.spandidos-publications.com/10.3892/ijo.2019.4706
   PubMed Web of Science ®Google Scholar
• Zhang Y, Liu Q, Wei W, et al. Bortezomib potentiates antitumor activity of mitoxantrone through dampening Wnt/β-catenin signal pathway in prostate cancer cells. BMC Cancer [Internet]. 2021;21(1):1101. doi: 10.1186/s12885-021-08841-1
   PubMed Web of Science ®Google Scholar
• Lee Y-J, Song H, Yoon YJ, et al. Ethacrynic acid inhibits STAT3 activity through the modulation of SHP2 and PTP1B tyrosine phosphatases in DU145 prostate carcinoma cells. Biochem Pharmacol [Internet]. 2020;175:113920. doi: 10.1016/j.bcp.2020.113920
   PubMed Web of Science ®Google Scholar
• Martí JM, Garcia-Diaz A, Delgado-Bellido D, et al. Selective modulation by PARP-1 of HIF-1α-recruitment to chromatin during hypoxia is required for tumor adaptation to hypoxic conditions. Redox Biol [Internet]. 2021;41:101885. doi: 10.1016/j.redox.2021.101885
   PubMed Web of Science ®Google Scholar
• de Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med [Internet]. 2020;382(22):2091–2102. doi: 10.1056/NEJMoa1911440
   PubMed Web of Science ®Google Scholar
• Mateo J, Porta N, Bianchini D, et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol [Internet]. 2020;21(1):162–174. doi: 10.1016/S1470-2045(19)30684-9
   PubMed Web of Science ®Google Scholar
• Kageyama Y, Sugiyama H, Ayame H, et al. Suppression of VEGF transcription in renal cell carcinoma cells by pyrrole-imidazole hairpin polyamides targeting the hypoxia responsive element. Acta Oncol (Madr). 2006;45:317–324. Available from. doi: 10.1080/02841860500486648
   PubMed Web of Science ®Google Scholar
• Yang F, Nickols NG, Li BC, et al. Antitumor activity of a pyrrole-imidazole polyamide. Proc Natl Acad Sci, USA. 2013;110(5):1863–1868. Available from: https://pnas.org/doi/full/10.1073/pnas.1222035110
   PubMed Web of Science ®Google Scholar
• Kurmis AA, Yang F, Welch TR, et al. A pyrrole-imidazole polyamide is active against enzalutamide-resistant prostate cancer. Cancer Res [Internet]. 2017;77(9):2207–2212. doi: 10.1158/0008-5472.CAN-16-2503
   PubMed Web of Science ®Google Scholar
• Ganapathy M, Ghosh R, Jianping X, et al. Involvement of FLIP in 2-methoxyestradiol–Induced tumor regression in transgenic adenocarcinoma of mouse prostate model. Clin Cancer Res [Internet]. 2009;15(5):1601–1611. doi: 10.1158/1078-0432.CCR-08-1389
   PubMed Web of Science ®Google Scholar
• Ghosh R, Ganapathy M, Alworth WL, et al. Corrigendum to “combination of 2-methoxyestradiol (2-ME2) and eugenol for apoptosis induction synergistically in androgen independent prostate cancer cells” [J. Steroid Biochem. Mol. Biol. 113 (2009) 25–35]. J Steroid Biochem Mol Biol. 2021;(213):105962. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0960076021001552
   PubMedGoogle Scholar
• Batth IS, Huang S-B, Villarreal M, et al. Evidence for 2-methoxyestradiol-mediated inhibition of receptor tyrosine kinase RON in the management of prostate cancer. Int J Mol Sci [Internet]. 2021;22(4):1852. doi: 10.3390/ijms22041852
   PubMed Web of Science ®Google Scholar
• Mabjeesh NJ, Escuin D, LaVallee TM, et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell [Internet]. 2003;3(4):363–375. doi: 10.1016/S1535-6108(03)00077-1
   PubMed Web of Science ®Google Scholar
• Ryu S, Lim W, Bazer FW, et al. Chrysin induces death of prostate cancer cells by inducing ROS and ER stress. J Cell Physiol [Internet]. 2017;232(12):3786–3797. doi: 10.1002/jcp.25861
   PubMed Web of Science ®Google Scholar
• Altabbal S, Athamnah K, Rahma A, et al. Propolis: A Detailed Insight of its anticancer molecular mechanisms. Pharmaceuticals [Internet]. 2023;16(3):450. doi: 10.3390/ph16030450
   Web of Science ®Google Scholar
• Pavese JM, Krishna SN, Bergan RC. Genistein inhibits human prostate cancer cell detachment, invasion, and metastasis. Am J Clin Nutr [Internet]. 2014;100:431S–436S. doi: 10.3945/ajcn.113.071290
   PubMed Web of Science ®Google Scholar
• Lakshman M, Xu L, Ananthanarayanan V, et al. Dietary genistein inhibits metastasis of human prostate cancer in mice. Cancer Res [Internet]. 2008;68(6):2024–2032. doi: 10.1158/0008-5472.CAN-07-1246
   PubMed Web of Science ®Google Scholar
• SZLISZKA E, ZYDOWICZ G, MIZGALA E, et al. Artepillin C (3,5-diprenyl-4-hydroxycinnamic acid) sensitizes LNCaP prostate cancer cells to TRAIL-induced apoptosis. Int J Oncol [Internet]. 2012;41(3):818–828. doi: 10.3892/ijo.2012.1527
   PubMed Web of Science ®Google Scholar
• Tseng J-C, Lin C-Y, Su L-C, et al. CAPE suppresses migration and invasion of prostate cancer cells via activation of non-canonical Wnt signaling. Oncotarget [Internet]. 2016;7(25):38010–38024. doi: 10.18632/oncotarget.9380
   PubMedGoogle Scholar
• Nair HK, Rao KVK, Aalinkeel R, et al. Inhibition of prostate cancer cell colony formation by the flavonoid quercetin correlates with modulation of specific regulatory genes. Clin Vaccin Immunol [Internet]. 2004;11(1):63–69. doi: 10.1128/CDLI.11.1.63-69.2004
   Google Scholar
• Puppo M, Battaglia F, Ottaviano C, et al. Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1α and -2α. Mol Cancer Ther [Internet]. 2008;7(7):1974–1984. doi: 10.1158/1535-7163.MCT-07-2059
   PubMed Web of Science ®Google Scholar
• Hörmann V, Kumi-Diaka J, Durity M, et al. Anticancer activities of genistein-topotecan combination in prostate cancer cells. J Cell Mol Med [Internet]. 2012;16(11):2631–2636. doi: 10.1111/j.1582-4934.2012.01576.x
   PubMed Web of Science ®Google Scholar
• Hu Y, Sun H, Owens RT, et al. Decorin suppresses prostate tumor growth through inhibition of epidermal growth factor and androgen receptor pathways. Neoplasia [Internet]. 2009;11(10):1042–1053. doi: 10.1593/neo.09760
   PubMed Web of Science ®Google Scholar
• Li H-X, Gao J-M, Liang J-Q, et al. Vitamin D 3 potentiates the growth inhibitory effects of metformin in DU145 human prostate cancer cells mediated by AMPK/mTOR signalling pathway. Clin Exp Pharmacol Physiol [Internet]. 2015;42(6):711–717. doi: 10.1111/1440-1681.12409
   PubMed Web of Science ®Google Scholar
• Thakur MK, Heilbrun LK, Sheng S, et al. A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study. Invest New Drugs [Internet]. 2016;34(1):112–118. doi: 10.1007/s10637-015-0307-6
   PubMed Web of Science ®Google Scholar
• Ying W, Du Z, Sun L, et al. Ganetespib, a unique triazolone-containing hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther [Internet]. 2012;11(2):475–484. doi: 10.1158/1535-7163.MCT-11-0755
   PubMed Web of Science ®Google Scholar
• Sun H-L, Liu Y-N, Huang Y-T, et al. YC-1 inhibits HIF-1 expression in prostate cancer cells: contribution of Akt/NF-κB signaling to HIF-1α accumulation during hypoxia. Oncogene [Internet]. 2007;26(27):3941–3951. doi: 10.1038/sj.onc.1210169
   PubMed Web of Science ®Google Scholar
• Zhang J, Wu D, He Y, et al. Rapamycin inhibits AR signaling pathway in prostate cancer by interacting with the FK1 domain of FKBP51. Biochem Biophys Rep [Internet]. 2020;23:100778. doi: 10.1016/j.bbrep.2020.100778
   PubMedGoogle Scholar
• Manohar SM, Padgaonkar AA, Jalota-Badhwar A, et al. A novel inhibitor of hypoxia-inducible factor-1α P3155 also modulates PI3K pathway and inhibits growth of prostate cancer cells. BMC Cancer [Internet]. 2011;11(1):338. doi: 10.1186/1471-2407-11-338
   PubMedGoogle Scholar